Sort by
Items per page

Send to

Choose Destination

Search results

Items: 19


Substrate binding allosterically relieves autoinhibition of the pseudokinase TRIB1.

Jamieson SA, Ruan Z, Burgess AE, Curry JR, McMillan HD, Brewster JL, Dunbier AK, Axtman AD, Kannan N, Mace PD.

Sci Signal. 2018 Sep 25;11(549). pii: eaau0597. doi: 10.1126/scisignal.aau0597.


Fatty acid oxidation is associated with proliferation and prognosis in breast and other cancers.

Aiderus A, Black MA, Dunbier AK.

BMC Cancer. 2018 Aug 9;18(1):805. doi: 10.1186/s12885-018-4626-9.


A PAM50-Based Chemoendocrine Score for Hormone Receptor-Positive Breast Cancer with an Intermediate Risk of Relapse.

Prat A, Lluch A, Turnbull AK, Dunbier AK, Calvo L, Albanell J, de la Haba-Rodríguez J, Arcusa A, Chacón JI, Sánchez-Rovira P, Plazaola A, Muñoz M, Paré L, Parker JS, Ribelles N, Jimenez B, Bin Aiderus AA, Caballero R, Adamo B, Dowsett M, Carrasco E, Martín M, Dixon JM, Perou CM, Alba E.

Clin Cancer Res. 2017 Jun 15;23(12):3035-3044. doi: 10.1158/1078-0432.CCR-16-2092. Epub 2016 Nov 30.


Accurate Prediction and Validation of Response to Endocrine Therapy in Breast Cancer.

Turnbull AK, Arthur LM, Renshaw L, Larionov AA, Kay C, Dunbier AK, Thomas JS, Dowsett M, Sims AH, Dixon JM.

J Clin Oncol. 2015 Jul 10;33(20):2270-8. doi: 10.1200/JCO.2014.57.8963. Epub 2015 Jun 1.


Integrative analyses identify modulators of response to neoadjuvant aromatase inhibitors in patients with early breast cancer.

López-Knowles E, Wilkerson PM, Ribas R, Anderson H, Mackay A, Ghazoui Z, Rani A, Osin P, Nerurkar A, Renshaw L, Larionov A, Miller WR, Dixon JM, Reis-Filho JS, Dunbier AK, Martin LA, Dowsett M.

Breast Cancer Res. 2015 Mar 11;17:35. doi: 10.1186/s13058-015-0532-0.


Differences in the transcriptional response to fulvestrant and estrogen deprivation in ER-positive breast cancer.

Patani N, Dunbier AK, Anderson H, Ghazoui Z, Ribas R, Anderson E, Gao Q, A'hern R, Mackay A, Lindemann J, Wellings R, Walker J, Kuter I, Martin LA, Dowsett M.

Clin Cancer Res. 2014 Aug 1;20(15):3962-73. doi: 10.1158/1078-0432.CCR-13-1378. Epub 2014 Jun 10.


Effect of aromatase inhibition on functional gene modules in estrogen receptor-positive breast cancer and their relationship with antiproliferative response.

Gao Q, Patani N, Dunbier AK, Ghazoui Z, Zvelebil M, Martin LA, Dowsett M.

Clin Cancer Res. 2014 May 1;20(9):2485-94. doi: 10.1158/1078-0432.CCR-13-2602. Epub 2014 Mar 14.


Comparison of PAM50 risk of recurrence score with oncotype DX and IHC4 for predicting risk of distant recurrence after endocrine therapy.

Dowsett M, Sestak I, Lopez-Knowles E, Sidhu K, Dunbier AK, Cowens JW, Ferree S, Storhoff J, Schaper C, Cuzick J.

J Clin Oncol. 2013 Aug 1;31(22):2783-90. doi: 10.1200/JCO.2012.46.1558. Epub 2013 Jul 1.


Molecular profiling of aromatase inhibitor-treated postmenopausal breast tumors identifies immune-related correlates of resistance.

Dunbier AK, Ghazoui Z, Anderson H, Salter J, Nerurkar A, Osin P, A'hern R, Miller WR, Smith IE, Dowsett M.

Clin Cancer Res. 2013 May 15;19(10):2775-86. doi: 10.1158/1078-0432.CCR-12-1000. Epub 2013 Mar 14.


ESR1 is co-expressed with closely adjacent uncharacterised genes spanning a breast cancer susceptibility locus at 6q25.1.

Dunbier AK, Anderson H, Ghazoui Z, Lopez-Knowles E, Pancholi S, Ribas R, Drury S, Sidhu K, Leary A, Martin LA, Dowsett M.

PLoS Genet. 2011 Apr;7(4):e1001382. doi: 10.1371/journal.pgen.1001382. Epub 2011 Apr 28.


Association between breast cancer subtypes and response to neoadjuvant anastrozole.

Dunbier AK, Anderson H, Ghazoui Z, Salter J, Parker JS, Perou CM, Smith IE, Dowsett M.

Steroids. 2011 Jul;76(8):736-40. doi: 10.1016/j.steroids.2011.02.025. Epub 2011 Apr 5.


Close and stable relationship between proliferation and a hypoxia metagene in aromatase inhibitor-treated ER-positive breast cancer.

Ghazoui Z, Buffa FM, Dunbier AK, Anderson H, Dexter T, Detre S, Salter J, Smith IE, Harris AL, Dowsett M.

Clin Cancer Res. 2011 May 1;17(9):3005-12. doi: 10.1158/1078-0432.CCR-10-1704. Epub 2011 Feb 15. Erratum in: Clin Cancer Res. 2011 Jul 15;17(14):4915. Clin Cancer Res. 2011 May 1;17(9). doi:10.1158/1078-0432.CCR-11-1325.


New and translational perspectives of oestrogen deprivation in breast cancer.

Dunbier AK, Martin LA, Dowsett M.

Mol Cell Endocrinol. 2011 Jul 4;340(2):137-41. doi: 10.1016/j.mce.2010.12.034. Epub 2011 Jan 19. Review.


Relationship between plasma estradiol levels and estrogen-responsive gene expression in estrogen receptor-positive breast cancer in postmenopausal women.

Dunbier AK, Anderson H, Ghazoui Z, Folkerd EJ, A'hern R, Crowder RJ, Hoog J, Smith IE, Osin P, Nerurkar A, Parker JS, Perou CM, Ellis MJ, Dowsett M.

J Clin Oncol. 2010 Mar 1;28(7):1161-7. doi: 10.1200/JCO.2009.23.9616. Epub 2010 Feb 1.


Progress in aromatase research and identification of key future directions.

Dunbier AK, Hong Y, Masri S, Brown KA, Sabnis GJ, Palomares MR.

J Steroid Biochem Mol Biol. 2010 Feb 28;118(4-5):311-5. doi: 10.1016/j.jsbmb.2009.09.005. Epub 2009 Sep 22.


Emerging biomarkers and new understanding of traditional markers in personalized therapy for breast cancer.

Dowsett M, Dunbier AK.

Clin Cancer Res. 2008 Dec 15;14(24):8019-26. doi: 10.1158/1078-0432.CCR-08-0974. Review.


Impact of estrogen deprivation on gene expression profiles of normal postmenopausal breast tissue in vivo.

Kendall A, Anderson H, Dunbier AK, Mackay A, Dexter T, Urruticoechea A, Harper-Wynne C, Dowsett M.

Cancer Epidemiol Biomarkers Prev. 2008 Apr;17(4):855-63. doi: 10.1158/1055-9965.EPI-07-2718.


N-terminal E-cadherin peptides act as decoy receptors for Listeria monocytogenes.

da Silva Tatley F, Aldwell FE, Dunbier AK, Guilford PJ.

Infect Immun. 2003 Mar;71(3):1580-3.


Methylation of the CDH1 promoter as the second genetic hit in hereditary diffuse gastric cancer.

Grady WM, Willis J, Guilford PJ, Dunbier AK, Toro TT, Lynch H, Wiesner G, Ferguson K, Eng C, Park JG, Kim SJ, Markowitz S.

Nat Genet. 2000 Sep;26(1):16-7.


Supplemental Content

Loading ...
Support Center